ClinicalTrials.gg
CompletedNCT04766086Updated May 24, 2024Results posted

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

A Phase 2 interventional study of Multivalent Group B streptococcus vaccine and Tetanus, diphtheria, and acellular pertussis vaccine in Group B Streptococcus Infections, sponsored by Pfizer. Completed at 12 sites in United States. Open to female participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-24.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Study summary

This phase 2B, placebo-controlled, randomized, observer-blinded trial will evaluate the safety, tolerability, and immunogenicity of the investigational multivalent group B streptococcus vaccine administered concomitantly with Tdap in healthy nonpregnant women 18 through 49 years of age.

02

Conditions studied

  • Group B Streptococcus Infections
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy women ≥18 and ≤49 years of age.
  • Participants who are willing and able to comply with scheduled visits, plan, laboratory tests, lifestyle considerations, and other study procedures, including completion of the e-diary from Day 1 to Day 7 following administration of investigational product.
  • Healthy females at enrollment who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Expected to be available for the duration of the study and who can be contacted by telephone during study participation.
  • Capable of giving personal signed .

Exclusion criteria

Exclusion Criteria:

  • Pregnant female participants; breastfeeding female participants; positive urine pregnancy test for women of (WOCBP) at Visit 1 (prior to vaccination)
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the product or any diphtheria toxoid-containing or CRM197-containing vaccine.
  • History of microbiologically proven invasive disease caused by group B streptococcus.
  • participants with known or suspected immunodeficiency.
  • Bleeding diathesis or condition associated with prolonged bleeding that would in the opinion of the investigator contraindicate intramuscular injection.
  • Other acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Previous vaccination with any licensed or investigational GBS vaccine, or planned receipt during the participant's participation in the study (through the 1-month follow-up visit [Visit 2]).
  • Vaccination within 5 years with tetanus and diphtheria toxoids and acellular pertussis-containing vaccines (Tdap) before investigational product administration.
  • Participants who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic
  • Vaccination with diphtheria- or CRM197-containing vaccine(s) from 6 months before investigational product administration, or planned receipt through the 1-month follow-up visit.
  • Receipt or planned receipt of blood/plasma products or immunoglobulin, from 60 days before investigational product administration through the 1-month follow-up visit
  • Participation in other studies involving investigational drug(s) within 28 days prior to study entry and/or during study participation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
306 participants (actual)

Study arms

  • Experimental
    GBS6 and Tdap

    Multivalent group B streptococcus vaccine and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)

    Biological: Multivalent Group B streptococcus vaccine · Biological: Tetanus, diphtheria, and acellular pertussis vaccine

  • Experimental
    GBS6 and Placebo

    Multivalent group B streptococcus vaccine and Placebo

    Biological: Multivalent Group B streptococcus vaccine · Biological: Placebo

  • Experimental
    Placebo and Tdap

    Placebo and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)

    Biological: Tetanus, diphtheria, and acellular pertussis vaccine · Biological: Placebo

Interventions

  • BiologicalMultivalent Group B streptococcus vaccine

    Multivalent Group B streptococcus vaccine

  • BiologicalTetanus, diphtheria, and acellular pertussis vaccine

    Tetanus, diphtheria, and acellular pertussis vaccine

    Also known as: Tdap

  • BiologicalPlacebo

    Saline control

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination

    Local reactions (redness, swelling, and pain at the injection site of the left arm) were recorded by participants in e-diary. Erythema/Redness and induration/swelling were measured and recorded in measuring device units (1 measuring device unit=0.5 centimeter \[cm\]). Grading: Grade 1/mild (greater than \[\>\] 2.0 to 5.0 cm), Grade 2/moderate (\>5.0 to 10.0 cm), Grade 3/severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as Grade 1/mild (did not interfere with activity), Grade2/moderate (interfered with activity), Grade 3/severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person.

    Time frame: Day 1 (day of vaccination) to Day 7

  2. Percentage of Participants Reporting Systemic Reactions Within 7 Days After Vaccination

    Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Nausea/vomiting was graded as: Grade 1/mild (1-2 times in 24 hours \[h\]), Grade 2/moderate: (\>2 times in 24h), Grade 3/severe (required intravenous hydration) and Grade 4 (ER visit/hospitalization for hypotensive shock). Diarrhea was graded as: Grade 1/mild (2-3 loose stools in 24h), Grade 2/moderate (4-5 loose stools in 24h), Grade 3/severe (6 or more loose stools in 24h) and Grade 4 (ER visit/hospitalization for severe diarrhea). Fatigue/tiredness, headache, chills, muscle pain and joint pain were graded as: Grade 1/mild (did not interfere with activity), Grade 2/moderate (some interference with activity), Grade 3/severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Grade 4 were classified by investigator or medically qualified person.

    Time frame: Day 1 (day of vaccination) to Day 7

  3. Percentage of Participants Reporting Adverse Events (AEs) Through 1 Month After Vaccination

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. In this outcome measure results excluded data for local reactions and systemic events.

    Time frame: Day 1 (day of vaccination) through 1 Month post-vaccination

  4. Percentage of Participants Reporting Medically Attended Adverse Events (MAEs) and Serious Adverse Events (SAEs) Through 6 Months After Vaccination

    A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect; or that was considered as an important medical event.

    Time frame: Day 1 (day of vaccination) through 6 Months post-vaccination

  5. Percentage of Participants Achieving Anti-tetanus Toxoid (Anti-TTd) and Anti-diphtheria Toxoid (Anti-DTd) Antibody Concentration >=0.1 IU/mL at 1 Month After Vaccination: GBS6 + Tdap and Placebo + Tdap Groups

    IU/mL stands for international units per milliliter.

    Time frame: 1 Month after Vaccination (Day 1, day of vaccination)

  6. Geometric Mean Concentration (GMC) of Anti-Pertussis Toxin (PT), Anti-Filamentous Hemagglutinin (FHA), and Anti-Pertactin (PRN) Antibodies; GMR of Anti-PT, Anti-FHA, and Anti-PRN for GBS6 + Tdap to Placebo + Tdap at 1 Month After Vaccination

    GMCs of anti-PT, anti-FHA, and anti-PRN was reported as descriptive data for the GBS6 +Tdap and placebo + Tdap groups, along with associated 2-sided 95% confidence interval. GMR for anti-PT, anti-FHA and anti-PRN antibodies were estimated from the GBS6 + Tdap group to the placebo + Tdap group and reported as statistical data.

    Time frame: 1 Month after Vaccination (Day 1, day of vaccination)

  7. GMC of GBS Capsular Polysaccharide (CPS) Serotype-Specific Immunoglobulin G (IgG) Antibodies; GMR of GBS CPS Serotype-specific IgG Antibodies for GBS6 + Tdap to Placebo + Tdap at 1 Month After Vaccination

    GBS CPS serotype-specific IgG GMCs (Ia, Ib, II, III, IV, V) were reported as descriptive data for the GBS6+Tdap and GBS6+placebo groups, along with associated 2-sided 95% confidence interval. GMR of GBS CPS serotype-specific IgG antibodies were estimated from the GBS6 + Tdap group to the placebo + Tdap group and reported as statistical data.

    Time frame: 1 Month after Vaccination (Day 1, day of vaccination)

07

Results

Posted May 24, 2024

Participant flow

Healthy non-pregnant female participants aged 18-49 years, were randomized to receive multivalent group B streptococcus 6-valent polysaccharide conjugate vaccine (GBS6) and tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap), or GBS6 and placebo, or placebo and Tdap.

Participant flow — Overall Study
MilestoneGBS6 + TdapGBS6 + PlaceboPlacebo + Tdap
Started10399104
Vaccinated10299103
Completed999398
Not completed466
Withdrew: Lost to follow-up353
Withdrew: Withdrawal by subject112
Withdrew: Other001

Outcome measures

PrimaryPercentage of Participants Reporting Local Reactions Within 7 Days After Vaccination

Local reactions (redness, swelling, and pain at the injection site of the left arm) were recorded by participants in e-diary. Erythema/Redness and induration/swelling were measured and recorded in measuring device units (1 measuring device unit=0.5 centimeter \[cm\]). Grading: Grade 1/mild (greater than \[\>\] 2.0 to 5.0 cm), Grade 2/moderate (\>5.0 to 10.0 cm), Grade 3/severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as Grade 1/mild (did not interfere with activity), Grade2/moderate (interfered with activity), Grade 3/severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person.

Time frame:
Day 1 (day of vaccination) to Day 7
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination
Percentage of participantsGBS6 + TdapGBS6 + PlaceboPlacebo + Tdap
Pain at injection site: Any39.2 (29.7 to 49.4)45.9 (35.8 to 56.3)33.0 (24.1 to 43.0)
Pain at injection site: Mild27.5 (19.1 to 37.2)35.7 (26.3 to 46.0)26.2 (18.0 to 35.8)
Pain at injection site: Moderate11.8 (6.2 to 19.6)9.2 (4.3 to 16.7)6.8 (2.8 to 13.5)
Pain at injection site: Severe0 (0.0 to 3.6)1.0 (0.0 to 5.6)0 (0.0 to 3.5)
Pain at injection site: Grade 40 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
Erythema/redness: Any7.8 (3.4 to 14.9)2.0 (0.2 to 7.2)0 (0.0 to 3.5)
Erythema/redness: Mild4.9 (1.6 to 11.1)1.0 (0.0 to 5.6)0 (0.0 to 3.5)
Erythema/redness: Moderate2.9 (0.6 to 8.4)1.0 (0.0 to 5.6)0 (0.0 to 3.5)
Erythema/redness: Severe0 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
Erythema/redness: Grade 40 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
Induration/swelling: Any3.9 (1.1 to 9.7)4.1 (1.1 to 10.1)1.9 (0.2 to 6.8)
Induration/swelling: Mild1.0 (0.0 to 5.3)2.0 (0.2 to 7.2)0 (0.0 to 3.5)
Induration/swelling: Moderate2.9 (0.6 to 8.4)2.0 (0.2 to 7.2)1.9 (0.2 to 6.8)
Induration/swelling: Severe0 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
Induration/swelling: Grade 40 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
PrimaryPercentage of Participants Reporting Systemic Reactions Within 7 Days After Vaccination

Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Nausea/vomiting was graded as: Grade 1/mild (1-2 times in 24 hours \[h\]), Grade 2/moderate: (\>2 times in 24h), Grade 3/severe (required intravenous hydration) and Grade 4 (ER visit/hospitalization for hypotensive shock). Diarrhea was graded as: Grade 1/mild (2-3 loose stools in 24h), Grade 2/moderate (4-5 loose stools in 24h), Grade 3/severe (6 or more loose stools in 24h) and Grade 4 (ER visit/hospitalization for severe diarrhea). Fatigue/tiredness, headache, chills, muscle pain and joint pain were graded as: Grade 1/mild (did not interfere with activity), Grade 2/moderate (some interference with activity), Grade 3/severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Grade 4 were classified by investigator or medically qualified person.

Time frame:
Day 1 (day of vaccination) to Day 7
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Reactions Within 7 Days After Vaccination
Percentage of participantsGBS6 + TdapGBS6 + PlaceboPlacebo + Tdap
Fever: >= 38.0°C1.0 (0.0 to 5.3)4.0 (1.1 to 10.1)2.9 (0.6 to 8.3)
Fever: 38.0°C to 38.4°C0 (0.0 to 3.6)2.0 (0.2 to 7.2)2.9 (0.6 to 8.3)
Fever: >38.4°C to 38.9°C1.0 (0.0 to 5.3)0 (0.0 to 3.7)0 (0.0 to 3.5)
Fever: >38.9°C to 40.0°C0 (0.0 to 3.6)2.0 (0.2 to 7.2)0 (0.0 to 3.5)
Fever: >40.0°C0 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
Nausea/vomiting: Any14.7 (8.5 to 23.1)17.2 (10.4 to 26.3)14.6 (8.4 to 22.9)
Nausea/vomiting: Mild7.8 (3.4 to 14.9)12.1 (6.5 to 20.4)12.6 (6.9 to 20.6)
Nausea/vomiting: Moderate6.9 (2.8 to 13.6)5.1 (1.7 to 11.5)1.9 (0.2 to 6.8)
Nausea/vomiting: Severe0 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
Nausea/vomiting: Grade 40 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
Diarrhea: Any19.6 (12.4 to 28.6)16.2 (9.2 to 25.2)21.4 (13.9 to 30.5)
Diarrhea: Mild15.7 (9.2 to 24.2)11.1 (5.7 to 19.2)13.6 (7.6 to 21.8)
Diarrhea: Moderate3.9 (1.1 to 9.7)4.0 (1.1 to 10.1)7.8 (3.4 to 14.7)
Diarrhea: Severe0 (0.0 to 3.6)1.0 (0.0 to 5.6)0 (0.0 to 3.5)
Diarrhea: Grade 40 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
Headache: Any35.3 (26.1 to 45.4)48.5 (38.3 to 58.7)38.8 (29.4 to 48.9)
Headache: Mild23.5 (15.7 to 33.0)34.3 (25.1 to 44.6)26.2 (18.0 to 35.8)
Headache: Moderate10.8 (5.5 to 18.5)13.1 (7.2 to 21.4)12.6 (6.9 to 20.6)
Headache: Severe1.0 (0.0 to 5.3)1.0 (0.0 to 5.5)0 (0.0 to 3.5)
Headache: Grade 40 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
Fatigue/tiredness: Any51.0 (40.9 to 61.0)50.5 (40.7 to 61.3)46.6 (36.7 to 56.7)
Fatigue/tiredness: Mild29.4 (20.8 to 39.3)21.2 (13.8 to 30.9)19.4 (12.3 to 28.4)
Fatigue/tiredness: Moderate20.6 (13.2 to 29.7)24.2 (16.4 to 34.2)26.2 (18.0 to 35.8)
Fatigue/tiredness: Severe1.0 (0.0 to 5.3)5.1 (1.7 to 11.5)1.0 (0.0 to 5.3)
Fatigue/tiredness: Grade 40 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
Muscle pain: Any30.4 (21.7 to 40.3)24.2 (16.4 to 34.2)26.2 (18.0 to 35.8)
Muscle pain: Mild14.7 (8.5 to 23.1)13.1 (7.3 to 21.6)14.6 (8.4 to 22.9)
Muscle pain: Moderate15.7 (9.2 to 24.2)10.1 (5.0 to 18.0)11.7 (6.2 to 19.5)
Muscle pain: Severe0 (0.0 to 3.6)1.0 (0.0 to 5.6)0 (0.0 to 3.5)
Muscle pain: Grade 40 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
Joint pain: Any17.6 (10.8 to 26.4)15.2 (8.8 to 24.0)12.6 (6.9 to 20.6)
Joint pain: Mild9.8 (4.8 to 17.3)10.1 (5.0 to 18.0)5.8 (2.2 to 12.2)
Joint pain: Moderate7.8 (3.4 to 14.9)3.0 (0.6 to 8.7)6.8 (2.8 to 13.5)
Joint pain: Severe0 (0.0 to 3.6)2.0 (0.2 to 7.2)0 (0.0 to 3.5)
Joint pain: Grade 40 (0.0 to 3.6)0 (0.0 to 3.7)0 (0.0 to 3.5)
PrimaryPercentage of Participants Reporting Adverse Events (AEs) Through 1 Month After Vaccination

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. In this outcome measure results excluded data for local reactions and systemic events.

Time frame:
Day 1 (day of vaccination) through 1 Month post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Adverse Events (AEs) Through 1 Month After Vaccination
Percentage of participantsGBS6 + TdapGBS6 + PlaceboPlacebo + Tdap
Percentage of Participants Reporting Adverse Events (AEs) Through 1 Month After Vaccination5.9 (2.2 to 12.4)8.1 (3.6 to 15.3)3.9 (1.1 to 9.6)
PrimaryPercentage of Participants Reporting Medically Attended Adverse Events (MAEs) and Serious Adverse Events (SAEs) Through 6 Months After Vaccination

A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect; or that was considered as an important medical event.

Time frame:
Day 1 (day of vaccination) through 6 Months post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Medically Attended Adverse Events (MAEs) and Serious Adverse Events (SAEs) Through 6 Months After Vaccination
Percentage of participantsGBS6 + TdapGBS6 + PlaceboPlacebo + Tdap
MAEs4.9 (1.6 to 11.1)4.0 (1.1 to 10.0)6.8 (2.8 to 13.5)
SAEs0 (0.0 to 3.6)0 (0.0 to 3.7)1.0 (0.0 to 5.3)
PrimaryPercentage of Participants Achieving Anti-tetanus Toxoid (Anti-TTd) and Anti-diphtheria Toxoid (Anti-DTd) Antibody Concentration >=0.1 IU/mL at 1 Month After Vaccination: GBS6 + Tdap and Placebo + Tdap Groups

IU/mL stands for international units per milliliter.

Time frame:
1 Month after Vaccination (Day 1, day of vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Anti-tetanus Toxoid (Anti-TTd) and Anti-diphtheria Toxoid (Anti-DTd) Antibody Concentration >=0.1 IU/mL at 1 Month After Vaccination: GBS6 + Tdap and Placebo + Tdap Groups
Percentage of participantsGBS6 + TdapPlacebo + Tdap
Anti-TTd100.0 (96.3 to 100.0)100.0 (96.4 to 100.0)
Anti-DTd100.0 (96.3 to 100.0)100.0 (96.4 to 100.0)
Statistical analysis
  • GBS6 + Tdap vs Placebo + Tdap · Risk difference: 0.0 · 95% CI -3.8 to 3.7
PrimaryGeometric Mean Concentration (GMC) of Anti-Pertussis Toxin (PT), Anti-Filamentous Hemagglutinin (FHA), and Anti-Pertactin (PRN) Antibodies; GMR of Anti-PT, Anti-FHA, and Anti-PRN for GBS6 + Tdap to Placebo + Tdap at 1 Month After Vaccination

GMCs of anti-PT, anti-FHA, and anti-PRN was reported as descriptive data for the GBS6 +Tdap and placebo + Tdap groups, along with associated 2-sided 95% confidence interval. GMR for anti-PT, anti-FHA and anti-PRN antibodies were estimated from the GBS6 + Tdap group to the placebo + Tdap group and reported as statistical data.

Time frame:
1 Month after Vaccination (Day 1, day of vaccination)
Reported as:
Geometric mean · Endotoxin units per milliliter (EU/mL)
Geometric Mean Concentration (GMC) of Anti-Pertussis Toxin (PT), Anti-Filamentous Hemagglutinin (FHA), and Anti-Pertactin (PRN) Antibodies; GMR of Anti-PT, Anti-FHA, and Anti-PRN for GBS6 + Tdap to Placebo + Tdap at 1 Month After Vaccination
Endotoxin units per milliliter (EU/mL)GBS6 + TdapPlacebo + Tdap
GMC of Anti-PT antibodies17.975 (14.519 to 22.254)32.916 (26.641 to 40.668)
GMC of Anti-FHA antibodies108.377 (93.479 to 125.650)191.140 (161.964 to 225.571)
GMC of Anti-PRN antibodies158.887 (132.346 to 190.751)270.294 (222.691 to 328.072)
Statistical analysis
  • GBS6 + Tdap vs Placebo + Tdap · Gmr: 0.546 · 95% CI 0.405 to 0.736
  • GBS6 + Tdap vs Placebo + Tdap · Gmr: 0.567 · 95% CI 0.455 to 0.707
  • GBS6 + Tdap vs Placebo + Tdap · Gmr: 0.588 · 95% CI 0.451 to 0.766
PrimaryGMC of GBS Capsular Polysaccharide (CPS) Serotype-Specific Immunoglobulin G (IgG) Antibodies; GMR of GBS CPS Serotype-specific IgG Antibodies for GBS6 + Tdap to Placebo + Tdap at 1 Month After Vaccination

GBS CPS serotype-specific IgG GMCs (Ia, Ib, II, III, IV, V) were reported as descriptive data for the GBS6+Tdap and GBS6+placebo groups, along with associated 2-sided 95% confidence interval. GMR of GBS CPS serotype-specific IgG antibodies were estimated from the GBS6 + Tdap group to the placebo + Tdap group and reported as statistical data.

Time frame:
1 Month after Vaccination (Day 1, day of vaccination)
Reported as:
Geometric mean · mcg/mL
GMC of GBS Capsular Polysaccharide (CPS) Serotype-Specific Immunoglobulin G (IgG) Antibodies; GMR of GBS CPS Serotype-specific IgG Antibodies for GBS6 + Tdap to Placebo + Tdap at 1 Month After Vaccination
mcg/mLGBS6 + TdapGBS6 + Placebo
Ia13.015 (7.095 to 23.874)14.616 (7.965 to 26.821)
Ib2.421 (1.322 to 4.431)2.106 (1.037 to 4.278)
II63.656 (40.279 to 100.600)61.709 (39.961 to 95.291)
III3.521 (2.107 to 5.885)5.547 (3.239 to 9.500)
IV6.065 (4.097 to 8.980)4.115 (2.746 to 6.167)
V1.307 (0.722 to 2.363)2.337 (1.209 to 4.517)
Statistical analysis
  • GBS6 + Tdap vs GBS6 + Placebo · Gmr: 0.890 · 95% CI 0.380 to 2.089
  • GBS6 + Tdap vs GBS6 + Placebo · Gmr: 1.149 · 95% CI 0.455 to 2.901
  • GBS6 + Tdap vs GBS6 + Placebo · Gmr: 1.032 · 95% CI 0.551 to 1.931
  • GBS6 + Tdap vs GBS6 + Placebo · Gmr: 0.635 · 95% CI 0.303 to 1.329
  • GBS6 + Tdap vs GBS6 + Placebo · Gmr: 1.474 · 95% CI 0.842 to 2.580
  • GBS6 + Tdap vs GBS6 + Placebo · Gmr: 0.559 · 95% CI 0.232 to 1.349

Adverse events

Collected over Local reaction and systemic events (systematic assessment): up to 7 days post-vaccination; All-cause mortality, SAEs, MAEs (non-systematic assessment): up to 6 months post-vaccination; Other AEs (non-systematic assessment): up to 1-month post-vaccination [vaccination was on Day 1]. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GBS6 + Tdap0/102 (0%)0/102 (0%)81/102 (79.4%)
GBS6 + Placebo0/99 (0%)0/99 (0%)71/99 (71.7%)
Placebo + Tdap0/103 (0%)1/103 (1%)79/103 (76.7%)
Most frequent serious events
Most frequent serious events
EventGBS6 + TdapGBS6 + PlaceboPlacebo + Tdap
Bile duct stoneHepatobiliary disorders0/1020/991/103
Most frequent other events
Showing 10 of 45
Most frequent other events
EventGBS6 + TdapGBS6 + PlaceboPlacebo + Tdap
Fatigue (FATIGUE)General disorders52/10250/9948/103
Headache (HEADACHE)Nervous system disorders36/10248/9940/103
Injection site pain (PAIN)General disorders40/10245/9934/103
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders31/10224/9927/103
Diarrhoea (DIARRHEA)Gastrointestinal disorders20/10216/9922/103
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders18/10215/9913/103
Vomiting (NAUSEA/VOMITING)Gastrointestinal disorders15/10217/9915/103
Injection site erythema (REDNESS)General disorders8/1022/990/103
Injection site swelling (SWELLING)General disorders4/1024/992/103
Pyrexia (FEVER)General disorders1/1024/993/103

Baseline characteristics

Safety set included all participants who received at least 1 dose of the study interventions and had at least 1 valid post dose safety assessment.

Age, Continuous
Age, Continuous(Years)GBS6 + TdapGBS6 + PlaceboPlacebo + TdapTotal
Mean35.4 ± 8.5434.8 ± 8.6035.5 ± 8.5935.3 ± 8.55
Sex: Female, Male
Sex: Female, Male(Participants)GBS6 + TdapGBS6 + PlaceboPlacebo + TdapTotal
Female10299103304
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GBS6 + TdapGBS6 + PlaceboPlacebo + TdapTotal
Hispanic or Latino8121636
Not Hispanic or Latino938686265
Unknown or Not Reported1113
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GBS6 + TdapGBS6 + PlaceboPlacebo + TdapTotal
American Indian or Alaska Native1304
Asian3519
Native Hawaiian or Other Pacific Islander0000
Black or African American18191956
White806875223
More than one race0448
Unknown or Not Reported0044
08

Study locations

12 sites
  • Alliance for Multispecialty Research, LLC
    Newton, Kansas 67114, United States
  • Quality Clinical Research, Inc
    Omaha, Nebraska 68114, United States
  • Alliance for Multispecialty Research, LLC
    Las Vegas, Nevada 89119, United States
  • Accellacare - Raleigh
    Raleigh, North Carolina 27609, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28401, United States
  • PriMED Clinical Research
    Dayton, Ohio 45419, United States
  • PriMed Clinical Research
    Dayton, Ohio 45429, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37909, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • DM Clinical Research - Brookline
    Houston, Texas 77081, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Apr 2023, 8 months.

Results were first posted in May 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2021
First posted
Feb 23, 2021
StartActual
Aug 12, 2022
Primary completionActual
Apr 27, 2023
CompletionActual
Apr 27, 2023
Results first posted
May 24, 2024
Last update
May 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04766086
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 23, 2021
Start date
Aug 12, 2022
Primary completion
Apr 27, 2023
Completion
Apr 27, 2023
Results posted
May 24, 2024
Last update
May 24, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion